Testing effectiveness (Phase 2)Looking for participantsNCT07169552What this trial is testingHC010 in First-line PD-L1 Positive Advanced NSCLC PatientsWho this might be right forNSCLC HC Biopharma Inc. 50
Large-scale testing (Phase 3)UnknownNCT05042375What this trial is testingA Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerWho this might be right forNon-small Cell Lung Cancer Jiangsu HengRui Medicine Co., Ltd. 450
Testing effectiveness (Phase 2)Looking for participantsNCT06070012What this trial is testingTebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal MelanomaWho this might be right forUveal Melanoma Diwakar Davar 44
Large-scale testing (Phase 3)UnknownNCT04203485What this trial is testingCamrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Who this might be right forPD-L1 Positive Non-small Cell Lung Cancer Jiangsu HengRui Medicine Co., Ltd. 762
Large-scale testing (Phase 3)Ended earlyNCT04128696What this trial is testingStudy of GSK3359609 and Pembrolizumab in Programmed Death Receptor 1-ligand 1 (PD-L1) Positive Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaWho this might be right forNeoplasms, Head and Neck GlaxoSmithKline 315
Testing effectiveness (Phase 2)Looking for participantsNCT05718323What this trial is testingNiraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLCWho this might be right forSCLC,Extensive StageSLFN11-positive ETOP IBCSG Partners Foundation 44
Large-scale testing (Phase 3)Looking for participantsNCT06295731What this trial is testingINBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCCWho this might be right forHead and Neck Squamous Cell Carcinoma (HNSCC) Inhibrx Biosciences, Inc 410
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07134556What this trial is testingPhase II Trial Evaluating the Safety and Efficacy of the Combination of Zimberelimab, Domvanalimab and Sacituzumab Govitecan as 1L Therapy for PD-L1 Positive Advanced TNBCWho this might be right forTriple Negative Breast CancerPDL-1 Positive MedSIR 25
Testing effectiveness (Phase 2)UnknownNCT04023916What this trial is testingSintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.Who this might be right forDiffuse Large B-Cell LymphomaSintilimabTP53 Mutation Chinese Academy of Medical Sciences 30
Early research (Phase 1)Looking for participantsNCT06084286What this trial is testingDual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid TumorsWho this might be right forAdvanced Solid Tumor Sichuan University 29
Not applicableUnknownNCT04322591What this trial is testingChemotherapy or Chemotherapy Plus PD-1 Antibody in RET Fusion Positive Advanced NSCLC Patitnts: the POSEIDON TrialWho this might be right forNon-small Cell Lung Cancer Hunan Province Tumor Hospital 70
Testing effectiveness (Phase 2)UnknownNCT05466019What this trial is testingA Prospective, Single Center Clinical Study of Toripalimab Combined With FLOT Regimen for Perioperative Treatment of PD-L1 Positive Locally Advanced Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GEJ)Who this might be right forPD-L1 Positive Locally Advanced Patients With Resectable Gastric Cancer The First Hospital of Jilin University 30
Testing effectiveness (Phase 2)UnknownNCT04886700What this trial is testingStudy of the SG001 Injection for Patients With Relapsed or Metastatic Uterine Cervical CancerWho this might be right forUterine Cervical Cancer CSPC ZhongQi Pharmaceutical Technology Co., Ltd. 104
Large-scale testing (Phase 3)Active Not RecruitingNCT05499390What this trial is testingAK112 in Advanced Non-Small Cell Lung CancerWho this might be right forAdvanced Non-small-cell Lung Cancer Akeso 398
Large-scale testing (Phase 3)Active Not RecruitingNCT05382286What this trial is testingStudy of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast CancerWho this might be right forTriple Negative Breast CancerPD-L1 Positive Gilead Sciences 443
Testing effectiveness (Phase 2)Active Not RecruitingNCT04392505What this trial is testingDurvalumab(MEDI4736) After chemoRadioTherapy(DART) for NSCLC-a Translational and Biomarker StudyWho this might be right forCancerNon Small Cell Lung CancerNon Small Cell Lung Cancer Stage III+2 more Oslo University Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06980272What this trial is testingSSGJ-707 in Advanced Non-Small Cell Lung CancerWho this might be right forAdvanced Non-Small Cell Lung Cancer Shenyang Sunshine Pharmaceutical Co., LTD. 420
Large-scale testing (Phase 3)UnknownNCT04568304What this trial is testingA Study Evaluating Toripalimab Injection Combined With Standard Chemotherapy as a First-line Treatment for Locally Advanced or Metastatic Urothelial CarcinomaWho this might be right forLocally Advanced or Metastatic Urothelial Carcinoma Shanghai Junshi Bioscience Co., Ltd. 364
Large-scale testing (Phase 3)Looking for participantsNCT06788990What this trial is testingFORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCCWho this might be right forMetastatic Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma Bicara Therapeutics 650
Large-scale testing (Phase 3)Looking for participantsNCT05549297What this trial is testingTebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)Who this might be right forAdvanced Melanoma Immunocore Ltd 540